Cyclodextrin-based polymers for therapeutic delivery
AssigneeNovartis AG
InventorScott Eliasof
Life of this patent
Estimating the term…
Abstract
Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.
Claims12
A method of treating a central nervous system (CNS) disorder in a subject, e.g., a human subject, comprising administering a CDP-therapeutic agent conjugate to the subject in an amount effective to treat the disorder.
A method of treating a neurological deficit in a subject, e.g., a human subject, the method comprising administering a CDP-therapeutic agent to the subject in an amount effective to treat the neurological deficit.
A method of treating a metabolic disorder in a subject, e.g., a human subject, comprising administering a CDP-therapeutic agent conjugate, to the subject in an amount effective to treat the disorder.
12-22. (canceled)
Dependencies are inferred from the claim text.